Fulcrum Therapeutics Stock (NASDAQ: FULC)

Fulcrum Therapeutics

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.

Biotech

Earnings

Earnings Beats

Mid Cap

News

Penny Stocks

Small Cap

Markets

Analyst Ratings

Trading Ideas

General

ANIP

FULC

IONS

KRYS

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced that the FDA has granted a Fast Track designation to its investigational RNA-targeted therapy zilganersen for treating Alexander disease (AxD), an ultra-rare neurological disorder.

IONS&#39; Rare Neurology Disorder Candidate Gets FDA&#39;s Fast Track Tag

Large Cap

BIIB

SAGE

Sage Therapeutics, Inc. (NASDAQ: SAGE) announced that partner Biogen (NASDAQ: BIIB) has terminated its rights related to the investigational neurology candidate, SAGE-324.

SAGE, BIIB End Collaboration for Neurology Candidate SAGE-324

BHVN

Shares of Biohaven Ltd. (NYSE: BHVN) were up 13.7% on Sept.

BHVN Stock Up as Rare Neurological Disease Study Meets Primary Goal

Fulcrum Therapeutics, Inc. - Common Stock

Fulcrum Therapeutics Inc

Press Releases

FULC INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Fulcrum Therapeutics, Inc. and Encourages Investors to Contact the Firm!

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fulcrum Therapeutics to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, November 13, 2024 at 8:00 a.m. ET

Health Care

Fulcrum Therapeutics to Participate in the Stifel Healthcare Conference

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2024

Fulcrum Therapeutics to Participate in Upcoming December Conferences

Fulcrum Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call and Webcast on Tuesday, February 25, 2025, at 8:00 a.m. ET

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2024

Aardvark Therapeutics, Inc. - Common Stock

Aardvark Therapeutics

Aclaris Therapeutics, Inc. - Common Stock

Aclaris Therapeutics

Alumis

Amylyx Pharmaceuticals, Inc. - Common Stock

Amylyx Pharma

Alto Neuroscience

Aquestive Therapeutics, Inc. - Common Stock

Aquestive Therapeutics

Atea Pharmaceuticals, Inc. - common stock

Atea Pharmaceuticals

Bioage Labs

Biote

Contineum Therapeutics, Inc. - Common stock

Contineum Therapeutics

Journey Medical Corporation - Common Stock

Journey Medical

Esperion Therapeutics, Inc. - Common Stock

Esperion Therapeutics

Milestone Pharmaceuticals Inc. - Common Shares

Milestone Pharmaceuticals

Nektar Therapeutics

Neumora Therapeutics, Inc. - Common Stock

Neumora Therapeutics

Pliant Therapeutics

Rapport Therapeutics, Inc. - Common Stock

Rapport Therapeutics

Cassava Sciences

scPharmaceuticals

Septerna

Telomir Pharmaceuticals, Inc. - Common Stock

Telomir Pharmaceuticals

Terns Pharmaceuticals, Inc. - Common Stock

Terns Pharma

Third Harmonic Bio

Ventyx Biosciences

Zhengye Biotechnology Holding Limited - Ordinary Shares

Comments

Fulcrum Therapeutics

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga